The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

• Published in: Therapeutic advances in medical oncology Vol. 12; p. 1758835920946156
• Main Authors: Wu, Shang-Gin, Yu, Chong-Jen, Yang, James Chih-Hsin, Shih, Jin-Yuan
• Format: Journal Article
• Language: English
• Published: London, England SAGE Publications 2020; Sage Publications Ltd; SAGE Publishing
• Subjects: Adenocarcinoma; Advances in Treatment of Lung Cancer Patients With Targetable Mutations; Epidermal growth factor; Epidermal growth factor receptors; Gefitinib; Inhibitor drugs; Lung cancer; Medical prognosis; Multivariate analysis; Mutation; Patients; Protein-tyrosine kinase receptors; Small cell lung carcinoma; EGFR mutation; afatinib; complex mutation; progression-free survival; lung adenocarcinoma

Background and aims: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are effective against classical EGFR mutations in lung cancer. However, their effectiveness and the prognosis of lung cancer patients with complex EGFR mutations are not well delineated. Therefore, we aimed...